Connor A., Lyons P., Kilgallon A., Simpson J., Perry A., and Lysaght J., 2024, Examining the evidence for immune checkpoint therapy in high-grade serous ovarian cancer, Heliyon, 10(20): e38888.
https://doi.org/10.1016/j.heliyon.2024.e38888

Gaillard S., Lacchetti C., Armstrong D., Cliby W., Edelson M., Garcia A., Ghebre R., Gressel G., Lesnock J., Meyer L., Moore K., O'Cearbhaill R., Olawaiye A., Salani R., Sparacio D., Van Driel W., and Tew W., 2025, Neoadjuvant chemotherapy for newly diagnosed advanced ovarian cancer: ASCO guideline update, Journal of Clinical Oncology, 43(7): 868-891.
https://doi.org/10.1200/jco-24-02589

Garlisi B., Lauks S., Aitken C., Ogilvie L., Lockington C., Petrik D., Eichhorn J., and Petrik J., 2024, The complex tumor microenvironment in ovarian cancer: therapeutic challenges and opportunities, Current Oncology, 31(7): 3826-3844.
https://doi.org/10.3390/curroncol31070283

Ghisoni E., Morotti M., Sarivalasis A., Grimm A., Kandalaft L., Laniti D., and Coukos G., 2024, Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach, Nature Reviews Clinical Oncology, 21(11): 801-817.
https://doi.org/10.1038/s41571-024-00937-4

Ghose A., McCann L., Makker S., Mukherjee U., Gullapalli S., Erekkath J., Shih S., Mahajan I., Sánchez E., Uccello M., Moschetta M., Adeleke S., and Boussios S., 2024, Diagnostic biomarkers in ovarian cancer: advances beyond CA125 and HE4, Therapeutic Advances in Medical Oncology, 16: 17588359241233225.
https://doi.org/10.1177/17588359241233225

Gitto S., Ihewulezi C., and Powell D., 2024, Adoptive T cell therapy for ovarian cancer, Gynecologic Oncology, 186: 77-84.
https://doi.org/10.1016/j.ygyno.2024.04.001

Hardy-Bessard A., Pujade-Lauraine E., Moore R., Montestruc F., Redondo A., Mirza M., Cibula D., Ciuleanu T., Gilbert L., Eitan R., Zagouri F., Pignata S., Glasspool R., Pfisterer J., Phaëton R., Anderson C., Rodrigues M., Gaba L., Bakirtzi E., Fauci J., Kalbacher E., Musa F., Gorman S., Duska L., Gladieff L., Braly P., Joly F., Pepin T., Ray-Coquard I., and Moore K., 2025, Dostarlimab and niraparib in primary advanced ovarian cancer, Annals of Oncology, 36(12): 1503-1513.
https://doi.org/10.1016/j.annonc.2025.05.009

Hong M., and Ding D., 2025, Early diagnosis of ovarian cancer: a comprehensive review of the advances, challenges, and future directions, Diagnostics, 15(4): 406.
https://doi.org/10.3390/diagnostics15040406

Kefas J., and Flynn M., 2024, Unlocking the potential of immunotherapy in platinum-resistant ovarian cancer: rationale, challenges, and novel strategies, Cancer Drug Resistance, 7: 39.
https://doi.org/10.20517/cdr.2024.67

Li D., Pei K., Yu X., Qie M., Zhong L., and Song L., 2025, Advances in PD-1 and CTLA-4 dual-target immunotherapy for ovarian cancer, Frontiers in Immunology, 16: 1686532.
https://doi.org/10.3389/fimmu.2025.1686532

Lin X., Kang K., Chen P., Zeng Z.Y., Li G., Xiong W., Yi M., and Xiang B., 2024, Regulatory mechanisms of PD-1/PD-L1 in cancers, Molecular Cancer, 23(1): 108.
https://doi.org/10.1186/s12943-024-02023-w

Manitz J., D'Angelo S., Apolo A., Eggleton S., Bajars M., Bohnsack O., and Gulley J., 2022, Comparison of tumor assessments using RECIST 1.1 and irRECIST and association with overall survival, Journal for Immunotherapy of Cancer, 10(2): e003302.
https://doi.org/10.1136/jitc-2021-003302

Matulonis U.A., Shapira-Frommer R., Santin A., Lisyanskaya A., Pignata S., Vergote I., Raspagliesi F., Sonke G., Birrer M., Provencher D., Sehouli J., Colombo N., González-Martín A., Oaknin A., Ottevanger P., Rudaitis V., Katchar K., Wu H., Keefe S., Ruman J., and Ledermann J., 2019, Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase 2 KEYNOTE-100 study, Annals of Oncology, 30(7): 1080-1087.
https://doi.org/10.1093/annonc/mdz135

Morand S., Devanaboyina M., Staats H., Stanbery L., and Nemunaitis J., 2021, Ovarian cancer immunotherapy and personalized medicine, International Journal of Molecular Sciences, 22(12): 6532.
https://doi.org/10.3390/ijms22126532

Na J., Liu Y., Fang K., Tan Y., Liang P., Yan M., Chu J., Gao J., Chen D., and Zhang S., 2024, Unraveling the potential biomarkers of immune checkpoint inhibitors in advanced ovarian cancer: a comprehensive review, Investigational New Drugs, 42: 728-738.
https://doi.org/10.1007/s10637-024-01478-4

Nunes M., Bartosch C., Abreu M., Richardson A., Almeida R., and Ricardo S., 2024, Deciphering the molecular mechanisms behind drug resistance in ovarian cancer to unlock efficient treatment options, Cells, 13(9): 786.
https://doi.org/10.3390/cells13090786

Papageorgiou D., Liouta G., Pliakou E., Zachariou E., Sapantzoglou I., Prokopakis I., and Kontomanolis E., 2025, Management of advanced ovarian cancer: current clinical practice and future perspectives, Biomedicines, 13(7): 1525.

Park H., Kim K., Pyo J., Suh C., Yoon S., Hatabu H., and Nishino M., 2020, Incidence of pseudoprogression during immune checkpoint inhibitor therapy for solid tumors: a systematic review and meta-analysis, Radiology, 297(1): 87-96.
https://doi.org/10.1148/radiol.2020200443